DelveInsight Releases Pipeline Report on Clostridium Difficile Infections
DelveInsight's "Clostridium Difficile Infections Pipeline Insight 2026" report analyzes over 20 companies and 22 drugs in development for Clostridium difficile infections globally.
Market research firm DelveInsight has published its "Clostridium Difficile Infections Pipeline Insight 2026" report, offering a comprehensive overview of the current drug development landscape for Clostridium difficile infections (CDI).
The report details more than 22 pipeline drugs being developed by over 20 companies. It provides insights into the clinical and non-clinical stages of these drug candidates, along with assessments based on product type, route of administration, and molecule type. The report also identifies inactive pipeline products.
Clostridium difficile is a bacterium that causes severe intestinal illness, notably as a hospital-acquired infection. Its incidence and severity have been increasing worldwide, posing a significant public health challenge. Transmission occurs via the fecal-oral route, with key risk factors including antibiotic therapy, advanced age, and healthcare facility stays.
Current treatments for CDI primarily include vancomycin and fidaxomicin. The development of novel therapies is crucial due to the potential for antibiotic resistance and the high rates of recurrent infections. The report, published in 2026, covers the global market.